Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEG-glutaminase/diazo-oxo-L-norleucine - New Medical Enzymes AG

Drug Profile

PEG-glutaminase/diazo-oxo-L-norleucine - New Medical Enzymes AG

Alternative Names: Diazo-oxo-L-norleucine/PEG-glutaminase; Diazooxonorleucine/PEG-glutaminase; DON/PEG-PGA; GlutaDON; PEG-glutaminase/diazooxonorleucine; PEG-PGA/DON

Latest Information Update: 08 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator New Medical Enzymes AG
  • Class Antineoplastics; Azo compounds; Glutaminase; Norleucines
  • Mechanism of Action DNA synthesis inhibitors; Glutamine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 08 Aug 2019 No development reported - Phase-I/II for Colorectal cancer (Metastatic disease) in Germany (IV)
  • 08 Aug 2019 No development reported - Phase-I/II for Gastric cancer in Germany, Poland (IV)
  • 08 Aug 2019 No development reported - Phase-I/II for Non-small cell lung cancer in Poland, Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top